CN116867514A - 用于异二聚化的正交突变 - Google Patents

用于异二聚化的正交突变 Download PDF

Info

Publication number
CN116867514A
CN116867514A CN202180091688.7A CN202180091688A CN116867514A CN 116867514 A CN116867514 A CN 116867514A CN 202180091688 A CN202180091688 A CN 202180091688A CN 116867514 A CN116867514 A CN 116867514A
Authority
CN
China
Prior art keywords
domain
sequence
amino acid
mutation
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180091688.7A
Other languages
English (en)
Chinese (zh)
Inventor
J·H·戴维斯
N·M·马歇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invenra Inc
Original Assignee
Invenra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invenra Inc filed Critical Invenra Inc
Publication of CN116867514A publication Critical patent/CN116867514A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180091688.7A 2020-12-10 2021-12-10 用于异二聚化的正交突变 Pending CN116867514A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123915P 2020-12-10 2020-12-10
US63/123,915 2020-12-10
PCT/US2021/062951 WO2022125986A1 (en) 2020-12-10 2021-12-10 Orthogonal mutations for heterodimerization

Publications (1)

Publication Number Publication Date
CN116867514A true CN116867514A (zh) 2023-10-10

Family

ID=81974005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180091688.7A Pending CN116867514A (zh) 2020-12-10 2021-12-10 用于异二聚化的正交突变

Country Status (10)

Country Link
US (2) US12312418B2 (cg-RX-API-DMAC7.html)
EP (1) EP4259194A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024500354A (cg-RX-API-DMAC7.html)
KR (1) KR20230118612A (cg-RX-API-DMAC7.html)
CN (1) CN116867514A (cg-RX-API-DMAC7.html)
AU (1) AU2021397322A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207821A1 (cg-RX-API-DMAC7.html)
IL (1) IL303518A (cg-RX-API-DMAC7.html)
MX (1) MX2023006899A (cg-RX-API-DMAC7.html)
WO (1) WO2022125986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Fc領域を含むモノマーポリペプチド及び使用方法
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EA032681B1 (ru) * 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
SG11201506451UA (en) * 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
JP6724023B2 (ja) * 2015-02-09 2020-07-15 リサーチ ディベロップメント ファウンデーション 改善された補体活性化を示す操作された免疫グロブリンfcポリペプチド
EP3511340B1 (en) * 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
DK3529269T3 (da) * 2016-10-19 2026-02-23 Invenra Inc Antistof-konstruktioner
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
IL274071B2 (en) * 2017-10-30 2025-10-01 Hoffmann La Roche Method for generating in vivo multispecific antibodies from monospecific antibodies
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules
PE20210320A1 (es) * 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
JP7812230B2 (ja) * 2019-04-25 2026-02-09 エフ. ホフマン-ラ ロシュ アーゲー ポリペプチド鎖交換による抗体由来ポリペプチドの生成
MX2022010176A (es) * 2020-02-20 2023-01-16 Win Therapeutics Inc Moléculas de unión biespecíficas a gd2 y b7h2 y métodos de uso.

Also Published As

Publication number Publication date
JP2024500354A (ja) 2024-01-09
US12312418B2 (en) 2025-05-27
US20260078202A1 (en) 2026-03-19
CA3207821A1 (en) 2022-06-16
EP4259194A1 (en) 2023-10-18
IL303518A (en) 2023-08-01
MX2023006899A (es) 2023-09-04
US20220363782A1 (en) 2022-11-17
AU2021397322A1 (en) 2023-07-06
AU2021397322A9 (en) 2024-06-20
EP4259194A4 (en) 2025-03-19
WO2022125986A1 (en) 2022-06-16
KR20230118612A (ko) 2023-08-11

Similar Documents

Publication Publication Date Title
CN107207592B (zh) 结构域交换的抗体
US10562982B2 (en) Methods for producing Fabs and bi-specific antibodies
JP7138046B2 (ja) 二特異性抗体基幹
US20260078202A1 (en) Orthogonal mutations for heterodimerization
JP2017046720A (ja) 操作されたヘテロ二量体タンパク質ドメイン
JP7123063B2 (ja) 抗体ドメインの好ましい対形成
TW200932269A (en) Bivalent, bispecific antibodies
KR20200067197A (ko) 단일특이적 항체로부터 다중특이적 항체의 생성 방법
CN104302665A (zh) 与新生儿Fc受体的结合增强的变体Fc多肽
CN111093702A (zh) 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗
EP3728328A1 (en) Bispecific antigen binding construct

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination